The US FDA should do more to engage biopharma manufacturers early in development on the establishment of expanded access programs, and to clarify how data from such programs may be used to support regulatory decisions, a new report states.
An independent assessment of FDA’s expanded access (EA) pathway found that while patients', physicians' and manufacturers’ overall perceptions of the...





